CLINICAL TRIALS PROFILE FOR HYPAQUE-CYSTO

All Clinical Trials for HYPAQUE-CYSTO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	Eli Lilly and Company	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	National University Hospital, Singapore	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00814866 ↗	Bone Resorption, Osteoclastogenesis and Adalimumab	Completed	Abbott	N/A	2008-09-01	Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti-TNF therapy on the number of osteoclast precursors in the peripheral blood of patients with Rheumatoid Arthritis, on in vitro osteoclastogenesis and on osteoclast activity before and during the treatment of patients with Rheumatoid Arthritis with Adalimumab.
NCT00814866 ↗	Bone Resorption, Osteoclastogenesis and Adalimumab	Completed	Université de Sherbrooke	N/A	2008-09-01	Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti-TNF therapy on the number of osteoclast precursors in the peripheral blood of patients with Rheumatoid Arthritis, on in vitro osteoclastogenesis and on osteoclast activity before and during the treatment of patients with Rheumatoid Arthritis with Adalimumab.

Clinical Trial Conditions for HYPAQUE-CYSTO

Condition Name

Condition Name for HYPAQUE-CYSTO
Intervention	Trials
Decompensated Cirrhosis	1
Lymphoma, Follicular	1
Non Small Cell Lung Cancer	1
Rheumatoid Arthritis	1

Condition MeSH

Condition MeSH for HYPAQUE-CYSTO
Intervention	Trials
Lymphoma	1
Bone Resorption	1
Arthritis, Rheumatoid	1
Liver Cirrhosis	1

Clinical Trial Locations for HYPAQUE-CYSTO

Trials by Country

Trials by Country for HYPAQUE-CYSTO
Location	Trials
United States	4
India	1
Canada	1

Trials by US State

Trials by US State for HYPAQUE-CYSTO
Location	Trials
Rhode Island	1
North Carolina	1
New Hampshire	1
Maine	1

Clinical Trial Progress for HYPAQUE-CYSTO

Clinical Trial Phase

Clinical Trial Phase for HYPAQUE-CYSTO
Clinical Trial Phase	Trials
Phase 2	2
N/A	2

Clinical Trial Status

Clinical Trial Status for HYPAQUE-CYSTO
Clinical Trial Phase	Trials
Completed	3
Not yet recruiting	1

Clinical Trial Sponsors for HYPAQUE-CYSTO

Sponsor Name

Sponsor Name for HYPAQUE-CYSTO
Sponsor	Trials
Université de Sherbrooke	1
Cephalon	1
Spectrum Pharmaceuticals, Inc	1

Sponsor Type

Sponsor Type for HYPAQUE-CYSTO
Sponsor	Trials
Industry	4
Other	4

Last updated: May 23, 2026

HYPAQUE-CYSTO clinical trials update, market analysis, and forecast (2024-2035)

Insufficient public information exists to produce a complete and accurate clinical-trials update, market sizing, or projection for HYPAQUE-CYSTO.

No actionable sources can be cited for: (1) current trial status (NCT/IRCT numbers, enrollment, endpoints, timelines), (2) regulatory status (FDA/EMA/UKMHRA approvals, labels, sanctions, and pathway), or (3) commercial benchmarks (WAC/AWP, prescription volumes, country coverage, payer mix, or historic sales) under the product name HYPAQUE-CYSTO.

How many clinical trials does HYPAQUE-CYSTO have in progress?

No validated trial registry entries can be cited for HYPAQUE-CYSTO under major public databases (e.g., ClinicalTrials.gov, EU Clinical Trials Register) using the provided name.

What are the latest HYPAQUE-CYSTO efficacy and safety results?

No peer-reviewed or registry-reported efficacy/safety datasets can be cited for HYPAQUE-CYSTO under the provided name.

What is HYPAQUE-CYSTO’s FDA or EMA approval status and label indication?

No verifiable FDA/EMA product record can be cited for HYPAQUE-CYSTO under the provided name, including no Orange Book listing (if applicable), no EPAR/SmPC record, and no authorization timeline.

What market does HYPAQUE-CYSTO serve and what is its therapeutic category?

No verifiable commercial footprint can be cited for HYPAQUE-CYSTO using the provided name, including no country-level sales reporting, tender history, procurement data, or reimbursement classification.

How big is the HYPAQUE-CYSTO addressable market (TAM/SAM/SOM)?

No credible segmentation inputs can be cited (patient counts, diagnostic volumes, procedure frequency, geographic adoption, competitive mix), so a defensible TAM/SAM/SOM model cannot be produced.

What is HYPAQUE-CYSTO’s pricing benchmark and unit economics?

No citable pricing datapoints (WAC/AWP, private payer net, tender pricing, or distributor margin structure) can be used to anchor unit economics.

What competitive products displace HYPAQUE-CYSTO in cystography or imaging workflows?

No validated competitive set can be cited for HYPAQUE-CYSTO using the provided name, including no mapping to active ingredient class, formulation type, or specific comparator brands.

What is the revenue forecast for HYPAQUE-CYSTO through 2035?

A forecast requires anchored historical sales, adoption curves, and regulatory/trial milestones that cannot be sourced for HYPAQUE-CYSTO using the provided name.

What are the key risks to HYPAQUE-CYSTO market penetration (regulatory, manufacturing, reimbursement)?

No product-specific regulatory or manufacturing constraints can be cited for HYPAQUE-CYSTO using the provided name.

How does HYPAQUE-CYSTO compare with alternative cystography contrast products?

No comparable labeled products, indications, or comparable trial designs can be cited for HYPAQUE-CYSTO using the provided name.

Key Takeaways

• A clinical trials update, market analysis, and projection for HYPAQUE-CYSTO cannot be produced with citable, product-specific facts under the provided name.
• No reliable sources can be cited for trial activity, regulatory status, or commercial performance metrics tied to HYPAQUE-CYSTO.

FAQs

1. What clinical trial endpoints are typically used for urinary tract contrast agents in cystography?
2. How is reimbursement usually structured for diagnostic imaging contrast products across major markets?
3. What regulatory pathways govern contrast agents for urinary tract imaging in the US vs EU?
4. What manufacturing and sterility controls are most critical for sterile injectable/intra-cavity contrast products?
5. How do tender-driven purchasing patterns affect pricing and volume for diagnostic contrast agents?

References (APA)

1. No citations available for HYPAQUE-CYSTO under the provided name.